Allergan Signs an Exclusive Option and License Agreement with Exicure to Discover and Develop SNA-based Therapies for Hair Loss Disorders

 Allergan Signs an Exclusive Option and License Agreement with Exicure to Discover and Develop SNA-based Therapies for Hair Loss Disorders

Allergan Signs an Exclusive Option and License Agreement with Exicure to Discover and Develop SNA-based Therapies for Hair Loss Disorders

Shots:

  • Exicure to receive $25M upfront, up to $97.5/program development & regulatory milestones, ~$265/program commercial milestones, royalties on global sales of therapies developed under the collaboration and will conduct discovery and development in two programs for hair loss disorders like androgenetic alopecia
  • Allergan to get exclusive access and options to license SNA-based therapies developed under the collaboration. Post exercises an option, Allergan will be responsible for clinical development and commercialization of licensed therapies
  • Exicure’s SNA technology unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exciure’s lead program is in P-Ib/II study for patients with advanced solid tumors

Click here to­ read full press release/ article | Ref: Exicure | Image: Waco Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post